DISCOVER CMTRA
A highly interactive forum
ABOUT THE CANCER MOLECULAR THERAPEUTICS RESEARCH ASSOCIATION
The Full Story
Provides a dynamic platform for the most contemporary and controversial approaches to the treatment of cancer
Dedicates half of the formal presentation time to questions and answers to promote rigorous discussion
Welcomes an active dialog among investigators from industry, academia, government and, foundations
Enables informal and intimate (150 participants) networking for graduate students, postdoctoral fellows, residents and, early-stage and established investigators
Awards the top four poster presenters with the opportunity to orally present their research and attend next year’s conference free of charge
Builds on the legacy of more than two decades of annual conference
ANNUAL MEETINGS
Programs
The Cancer Molecular Therapeutics Research Association [CMTRA] was created in 2008 to organize and host the annual Molecular Therapeutics of Cancer meeting. The meeting objective is to provide a forum for presentation and discussion of contemporary research in the field of cancer drug development and therapy. Modeled after small Gordon-type conferences, the meeting provides an opportunity for young and established researchers to discuss and challenge current paradigms for cancer drug development and therapy, as well as a venue where novel ideas can be presented with anticipation of lively debate.
2021 CONFERENCE
Cancelled due to the COVID-19 Pandemic
2020 CONFERENCE
Cancelled due to the COVID-19 Pandemic
CMTRA
Officers & Board Members
PETER HOUGHTON, PH.D.
President
Director | Greehey Children's Cancer Research Institute | UT Health at San Antonio, San Antonio, TX
ROBERT KRAMER, PH.D.
Vice President
RAKramer Consulting LLC | Newton, PA
JAMES D. WINKLER, PH.D.
Secretary
Chief Scientific Officer | OnKure Therapeutics
WILLIAM J. PLACZEK, PH.D.
Treasurer
Associate Professor | Department of Biochemistry and Molecular Genetics; Director | Central Alabama High-Field NMR Facility; Co-Director | Structural Biology Shared Facility, Cancer Center | The University of Alabama at Birmingham
MARTIN MCMAHON, PH.D.
President Elect
Cumming-Presidential Professor of Cancer Biology & Senior Director for Preclinical Translation |
Huntsman Cancer Institute & Dept. of Dermatology | University of Utah | Salt Lake City, UT
LORI FRIEDMAN, PH.D.
Vice President Elect
Chief Scientific Officer | ORIC Pharmaceuticals | South San Francisco, CA
MARY-ANN BJORNSTI, PH.D.
Board Member
Professor & Chair Newman H Waters Chair of Clinical Pharmacology | Department of Pharmacology & Toxicology | University of Alabama at Birmingham
PHILLIP A. DENNIS, M.D., PH.D.
Board Member
Vice President Lung Cancer | Sanofi Oncology
SHIVA MALEK, PH.D.
Board Member
Global Head, Oncology | Novartis Institute of Biomedical Research
ZAHID H. SIDDIK, PH.D.
Board Member
Professor of Medicine | Pharmacology Department of Experimental Therapeutics | MD Anderson Cancer Center | Houston, TX
ELI M. WALLACE, PH.D.
Board Member
Chief Scientific Officer, Oncology | BridgeBio | Dallas, TX
BOB ABRAHAM, PH.D.
Board Member
Executive Vice President | Head of Cancer Biology | Odyssey Therapeutics
Emeritus Board Members:
Alan Eastman, Ph.D. - Professor Emeritus | Norris Cotton Cancer Center | Dartmouth College | Hanover, NH
John A. Hickman, D.Sc. - Agon Consulting, Paris
Branimir I. Sikic, M.D. - Director | Stanford Clinical & Translational Research Unit; Co-director | Stanford University School of Medicine | Stanford, CA
